Showing results (3971-3980 of 6,740) with videos related to

Sort By:
Pageof 674
Oncotargets and Therapy|November 2, 2016
High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cellsXue Chen, Qi Zhang, Youjun Luo, et al.
Oncotargets and Therapy|October 13, 2016
Combination of cold atmospheric plasma and iron nanoparticles in breast cancer: gene expression and apoptosis studyAzam Jalili, Shiva Irani, Reza Mirfakhraie
Oncotargets and Therapy|October 13, 2016
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsSameem M Abedin, Craig S Boddy, Hidayatullah G Munshi
Oncotargets and Therapy|October 13, 2016
Association analysis of DACT1 genetic variants and gastric cancer risk in a Chinese Han population: a case-control studyChi Huang, Younan Wang, Hao Fan, et al.
Oncotargets and Therapy|October 21, 2016
miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathwayBo Shen, Shaorong Yu, Yan Zhang, et al.
Oncotargets and Therapy|December 10, 2016
Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expressionFei Xue, Yanhui Liu, Hongwei Zhang, et al.
Oncotargets and Therapy|November 30, 2016
Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancerFan Yang, Shi-Xu Lv, Lin Lv, et al.
Oncotargets and Therapy|November 30, 2016
MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1Dan Xu, Xiaofeng Chen, Quanyong He, et al.
Oncotargets and Therapy|November 30, 2016
Meta-analysis of outcomes of patients with stage IV colorectal cancer managed with chemotherapy/radiochemotherapy with and without primary tumor resectionKo-Chao Lee, Yu-Che Ou, Wan-Hsiang Hu, et al.
Oncotargets and Therapy|November 30, 2016
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trialKevin J Harrington, Robert Hi Andtbacka, Frances Collichio, et al.
Pageof 674